Market Closed

ATR
AptarGroup
$ 143.09
0.97%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated a day ago

AptarGroup News

Latest AptarGroup Stock News & ATR Headlines

Atrium Therapeutics Reports Third Quarter 2026 Financial Results
2 days ago | prnewswire.com
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AptarGroup, Inc. (NYSE: ATR)
4 days ago | prnewswire.com
Rakovina Therapeutics to Present Brain-Penetrant ATR Inhibitor Data at the 31st Society for Neuro-Oncology Annual Meeting
10 days ago | globenewswire.com
Investing in AptarGroup (ATR)? Don't Miss Assessing Its International Revenue Trends
12 days ago | zacks.com
Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026
13 days ago | prnewswire.com
Aptar: 3 Key Takeaways for Long-Term Investors
13 days ago | fool.com
AptarGroup, Inc. (ATR) Q3 2026 Earnings Call Transcript
15 days ago | seekingalpha.com
What AptarGroup (ATR) Said on Its Q3 Earnings Call
15 days ago | marketbeat.com
AptarGroup (ATR) Q3 Earnings and Revenues Beat Estimates
16 days ago | zacks.com
Rakovina Therapeutics and Celvion Therapeutics Complete AI Analysis Identifying Priority Cancer Indications for Brain-Penetrant ATR Inhibitor Program
18 days ago | globenewswire.com
Load More

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

oinCodex Android App
CoinCodex Mobile App
Market Closed

ATR
AptarGroup
$ 143.09
0.97%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated a day ago